The deal closure removes overhang uncertainty and adds a recently approved, first-in-class commercial asset (VYKAT XR) with strong early adoption potential. The $600M initial draw on the new credit facility increases leverage but is manageable given Neurocrine's cash flow profile (INGREZZA). Focus on VYKAT XR revenue trajectory and integration execution are the key near-term catalysts. Monitor next quarterly report for initial VYKAT XR sales and updated 2026 guidance reflecting the acquisition.
NBIX drugs
NBIX drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 18 $156.73entry
- T+1 · 6mo ago −1.81%α −1.16% · $153.90
- T+5 · 6mo ago −0.64%α −2.26% · $155.72
- T+20 · 5mo ago +1.78%α −0.41% · $159.51
- T+60 · 3mo ago −0.15%α −4.73% · $156.49
Price Chart
How similar events traded
Executive Summary
Neurocrine Biosciences closed its $2.9B acquisition of Soleno Therapeutics on May 18, 2026, adding VYKAT XR (diazoxide choline) for hyperphagia in Prader-Willi syndrome to its rare disease portfolio. Concurrently, Neurocrine entered into a $1.0B senior secured revolving credit facility and borrowed $600M on the closing date to fund the acquisition and for general corporate purposes. The combination of the closed transformative acquisition and the new debt facility represents a significant strategic deployment of capital.
Key Financial Metrics
Key Facts
- Acquisition of Soleno Therapeutics closed on May 18, 2026, for total equity value of $2.9B ($53.00 per share in cash).
- 88.9% of Soleno shares (46,356,114 shares) validly tendered in the offer; remaining shares converted at same $53.00 per share in the merger.
- Addition of VYKAT XR, the first and only FDA-approved treatment for hyperphagia in Prader-Willi syndrome, a ~10,000-patient U.S. market.
- New $1.0B five-year senior secured revolving credit facility entered into on May 14, 2026, with an initial $600M draw.
- Total Net Leverage Ratio covenant of 3.75:1.00 (4.25:1.00 after qualifying acquisitions); minimum Interest Coverage Ratio of 2.00:1.00.
- Prior analysis on the April 6 deal announcement was bullish with an impact score of 8/10.
Financial Impact
Total equity value of $2.9 billion paid in cash, funded from available cash on hand. New $1.0 billion revolving credit facility established with $600 million drawn on closing.
Risk Factors
- Integration risk of Soleno operations and commercial launch.
- VYKAT XR market uptake may be slower than expected in the PWS indication.
- Increased leverage from the $600M draw and potential future draws; covenants tested quarterly.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-228013 |
| Document: d94926d8k.htm | 0001193125-26-228013 |
| Document: d94926dex991.htm | 0001193125-26-228013 |
| Document: 0001193125-26-228013-index-headers.html | 0001193125-26-228013 |
| Document: 0001193125-26-228013-index.html | 0001193125-26-228013 |
| Document: 0001193125-26-228013.txt | 0001193125-26-228013 |
Track record
30 reports on NBIX
2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +27.40% at T+60 after the Apr 6, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $174.41 Now $165.31 −5.22% settles Dec 10
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 2, 202614d ago Press Release Bullish 6/10 No price data
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
- Oct 30, 202617d ago 144 Neutral 1/10 Entry $145.35 Now $165.31 +13.73% settles Dec 1
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $146.10 Now $165.31 +13.15% settles Nov 30
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $145.53 Now $165.31 +13.59% settles Nov 25
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers